Business Context and Reporting Period
This Form 8-K Current Report is filed by Global Medical REIT Inc. (the "Company") on March 6, 2017, reporting events occurring on February 28, 2017, and March 3, 2017. The Company is a Maryland corporation operating as a real estate investment trust focused on medical properties. Note: The request metadata references "Chiron Real Estate Inc.," but the filing text explicitly identifies the registrant as "Global Medical REIT Inc."
Key Financial Metrics and Agreements
Debt and Liquidity
- Credit Facility Amendment: On March 3, 2017, the Company amended its senior revolving credit facility with BMO Harris Bank N.A. and other lenders.
- Commitment Amount: Increased to $200 million, with an accordion feature allowing for an additional $50 million subject to conditions.
- Interest Rates: Floating rate based on LIBOR plus 2.00% to 3.00% or Base Rate plus 1.00% to 2.00%, dependent on the consolidated leverage ratio.
- Unused Commitment Fee: 0.20% per annum if average daily unused commitments are less than 50%; 0.30% if 50% or greater.
- Lenders: Includes BMO Harris Bank N.A., Citizens Bank N.A., SunTrust Bank, The Huntington National Bank, Comerica Bank, KeyBank National Association, Franklin Synergy Bank, and Branch Banking and Trust Company.
Financial Covenants
- Maximum Consolidated Leverage Ratio: Less than 0.65:1.00 for quarters ending prior to October 1, 2019; 0.60:1.00 thereafter.
- Minimum Fixed Charge Coverage Ratio: 1.50:1.00.
- Minimum Net Worth: $119,781,219 plus 75% of net proceeds from subsequent equity offerings.
- Secured Recourse Debt Ratio: Total secured recourse debt to total asset value not greater than 0.10:1.00.
Note: The filing does not provide current revenue, profit, cash flow, or margin figures for the reporting period.
Material Changes and Executive Compensation
Executive Equity Awards (February 28, 2017)
The Board approved 2017 Annual Performance-Based and Long-Term Performance-Based Incentive Plan (LTIP) Awards for executive officers. Key targets include:
- Jeffrey Busch (Chairman & President): $110,000 Annual Award Target; $200,008 Long-Term Award Target.
- David Young (CEO): $100,000 Annual Award Target; $300,000 Long-Term Award Target.
- Donald McClure (CFO): $77,500 Annual Award Target; $75,000 Long-Term Award Target.
- Other Executives: Awards granted to General Counsel, CIO, SVP, and COO ranging from $50,000 to $92,500 for Annual Awards and $80,006 to $100,000 for Long-Term Awards.
Performance Goals for Annual Awards
Awards are split into five 20% components based on:
- Acquisitions: Target $500 million (Threshold $300M; Maximum $600M).
- Capital Raising: Target $200 million gross proceeds (Threshold $75M; Maximum $300M).
- Net Asset Value (NAV): Target $350 million (Threshold $250M; Maximum $450M).
- Adjusted FFO (AFFO) per Share: Target $0.20 for Q4 2017 (Threshold $0.18; Maximum $0.22).
- Discretionary Component: Based on individual performance.
Long-Term Award Performance
Based on a three-year period measuring Total Shareholder Return (TSR):
- Absolute TSR (75% weight): Target 30% return (Threshold 24%; Maximum 36%+).
- Relative TSR (25% weight): Target 55th percentile of SNL Healthcare REIT Index peers (Threshold 35th percentile; Maximum 75th percentile+).
Director Compensation
Annual compensation for independent directors set at $30,000 cash retainer and $30,000 equity award. Additional retainers apply for committee service and chair roles.
Guidance, Outlook, and Risks
The filing outlines specific financial targets for 2017 embedded within executive compensation plans, serving as implicit management guidance for acquisitions ($500M), capital raising ($200M), and NAV ($350M). The Company faces risks related to meeting the strict leverage and coverage covenants of the amended credit facility. Failure to meet performance thresholds in the LTIP plans will result in forfeiture of equity units.
Key Facts for Investor Verification
- Verify the Company's current consolidated leverage ratio to ensure compliance with the new 0.65:1.00 covenant limit.
- Confirm the status of the $200 million credit facility commitment and any drawdowns as of the filing date.
- Monitor progress toward the 2017 acquisition target of $500 million and capital raising target of $200 million, as these drive executive compensation.
- Review the specific terms of the "accordion feature" allowing for an additional $50 million in borrowing capacity.
- Check subsequent filings for Q4 2017 AFFO per share results to validate the $0.20 target used in compensation calculations.